Occudo Quantitative Strategies’s BridgeBio Pharma BBIO Stock Holding History

Occudo Quantitative Strategies’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-9,510	Closed	-$384K	–	741
2023 Q4	$384K	Buy	+9,510	New	+$286K	0.05%	465
2023 Q3	–	Sell	-20,311	Closed	-$349K	–	982
2023 Q2	$349K	Buy	+20,311	New	+$306K	0.04%	692
2022 Q4	–	Sell	-19,834	Closed	-$197K	–	972
2022 Q3	$197K	Buy	19,834 +730	+4%	+$7.58K	0.02%	967
2022 Q2	$173K	Sell	19,104 -122,094	-86%	-$1.02M	0.01%	942
2022 Q1	$1.43M	Buy	141,198 +123,410	+694%	+$1.27M	0.12%	267
2021 Q4	$297K	Buy	+17,788	New	+$753K	0.03%	771
2021 Q1	–	Sell	-3,987	Closed	-$284K	–	752
2020 Q4	$284K	Buy	+3,987	New	+$192K	0.09%	427

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Occudo Quantitative Strategies's BBIO Position: Q1 2024 in Review

Occudo Quantitative Strategies sold out of BridgeBio Pharma (BBIO) in Q1 2024, closing a stake of 9,510 shares — an estimated $384K sold.

Occudo Quantitative Strategies first reported a position in BBIO in Q4 2020 and held it in 7 quarters. The position peaked at $1.43M in Q1 2022. 244 funds tracked by Wall St. Rank hold BBIO as of Q1 2024.

Occudo Quantitative Strategies reported no remaining BridgeBio Pharma position as of Q1 2024 after selling out during the quarter.
Occudo Quantitative Strategies sold 9,510 BridgeBio Pharma shares in Q1 2024, an estimated $384K.
Occudo Quantitative Strategies first reported a position in BridgeBio Pharma in Q4 2020 and held it in 7 quarters.
Occudo Quantitative Strategies's BridgeBio Pharma position peaked at $1.43M in Q1 2022.
244 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2024.

Based on Occudo Quantitative Strategies's 13F filing for Q1 2024, filed 15 May 2024.